2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

Stockheads

2023-01-24

Link copied to clipboard

Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies.

In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.

Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.

To hear about the company’s upcoming 2023, click above.

Explore More

Investor Guide: Health & Biotech FY2023

Read MoreHealth

Link copied to clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

Featured Companies

ASX: PTX Prescient Therapeutics

You might be interested in

Year in Review

Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

December 1, 2022 | Stockhead TV

Prepped and Primed

2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner

January 23, 2023 | Stockhead TV

Health & Biotech

ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow

January 20, 2023 | Nadine McGrath

Sponsored Articles

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2305968169"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2305968169\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2305968169?lang=zh_TW&edition=fundamental","thumbnail":"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-Prescient-1-640x360.jpg","is_english":true,"pubTime":"2023-01-24 07:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2305968169","market":"us","top_or_hot":-1,"title":"2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke","media":"Stockheads","content":"<html><body><div>\n<main role=\"main\">\n<div><div></div></div>\n<div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div><p><strong>Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. </strong></p>\n<p>In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.</p>\n<p>Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.</p>\n<p><strong>To hear about the company’s upcoming 2023, click above.</strong></p>\n<span></span><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-1024x578.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-768x433.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-610x344.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-640x361.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1.jpg 1196w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2023</span> </li> </ul></div><div></div><div><span>Read More</span>Health</div><div></div><div><div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div>\n<div>\n<div></div>\n<div>\n<div>\n<button></button>\n<div>\n<div>\n<h2>SUBSCRIBE</h2><p>Get the latest Stockhead news delivered free to your inbox.</p> </div>\n<div>\n<div>\n<div>\n<p>\"<span>*</span>\" indicates required fields</p>\n</div><form action=\"/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/\" enctype=\"multipart/form-data\" method=\"post\" novalidate=\"\" target=\"gform_ajax_frame_2\">\n<div><div><div><label for=\"input_2_1\">Name<span><span>*</span></span></label><div><input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Name\" type=\"text\" value=\"\"/> </div></div><div><label for=\"input_2_2\">Email<span><span>*</span></span></label><div>\n<input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Email\" type=\"email\" value=\"\"/>\n</div></div><fieldset><div><i></i><span>Hidden</span></div><legend>Email Lists</legend><div><div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Morning Update\"/>\n<label for=\"choice_2_5_1\">Morning Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Lunch Update\"/>\n<label for=\"choice_2_5_2\">Lunch Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Market Close Update\"/>\n<label for=\"choice_2_5_3\">Market Close Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Weekend Update\"/>\n<label for=\"choice_2_5_4\">Weekend Update</label>\n</div></div></div></fieldset><div><label for=\"input_2_3\"></label><div></div></div></div></div>\n<div> <input type=\"submit\" value=\"Submit\"/> <input type=\"hidden\" value=\"form_id=2&amp;title=&amp;description=&amp;tabindex=0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"2\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"WyJbXSIsImQ5ODZkNzIwYjIxZjU4YzcxYzQzNTI1YjUzYTViYTYxIl0=\"/>\n<input type=\"hidden\" value=\"0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"\"/>\n</div>\n</form>\n</div>\n<p>\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t</p>\n</div>\n</div>\n<div>\n<p>\n\t\t\t\t\t\t\tBy proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.\n\t\t\t\t\t\t</p>\n</div>\n</div>\n</div>\n</div>\n</div><div> <h3>Featured Companies</h3> <ul><li> <span>ASX: PTX</span> <span>Prescient Therapeutics </span> </li></ul></div><div> <div> <h2>You might be interested in</h2> </div> <div><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics.jpg 1200w\" width=\"300\"/> </div> <header> <p>Year in Review</p> <h2>Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke</h2> <p> <span> <time datetime=\"2022-12-01 10:24:20\">December 1, 2022</time> <time datetime=\"2022-12-01 12:47:22\" december=\"\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust.jpg 1200w\" width=\"300\"/> </div> <header> <p>Prepped and Primed</p> <h2>2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner</h2> <p> <span> <time datetime=\"2023-01-23 09:30:23\">January 23, 2023</time> <time datetime=\"2023-01-23 13:46:10\" january=\"\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2023/01/Garden-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2023/01/Garden-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden.jpg 1200w\" width=\"300\"/> </div> <header> <p>Health &amp; Biotech</p> <h2>ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow</h2> <p> <span> <time datetime=\"2023-01-20 14:22:59\">January 20, 2023</time> <time datetime=\"2023-01-20 14:22:59\" january=\"\"> </time></span> |      <span> <span> Nadine McGrath </span> </span> </p> </header></article> </div></div>\n<div></div>\n<div></div>\n<div><h2>Sponsored Articles</h2></div>\n</main>\n</div></body></html>","source":"stockheads_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Stockheads</strong><span class=\"h-time small\">2023-01-24 07:14</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<main role=\"main\">\n<div><div></div></div>\n<div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div><p><strong>Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. </strong></p>\n<p>In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.</p>\n<p>Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.</p>\n<p><strong>To hear about the company’s upcoming 2023, click above.</strong></p>\n<span></span><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-1024x578.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-768x433.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-610x344.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-640x361.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1.jpg 1196w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2023</span> </li> </ul></div><div></div><div><span>Read More</span>Health</div><div></div><div><div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div>\n<div>\n<div></div>\n<div>\n<div>\n<button></button>\n<div>\n<div>\n<h2>SUBSCRIBE</h2><p>Get the latest Stockhead news delivered free to your inbox.</p> </div>\n<div>\n<div>\n<div>\n<p>\"<span>*</span>\" indicates required fields</p>\n</div><form action=\"/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/\" enctype=\"multipart/form-data\" method=\"post\" novalidate=\"\" target=\"gform_ajax_frame_2\">\n<div><div><div><label for=\"input_2_1\">Name<span><span>*</span></span></label><div><input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Name\" type=\"text\" value=\"\"/> </div></div><div><label for=\"input_2_2\">Email<span><span>*</span></span></label><div>\n<input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Email\" type=\"email\" value=\"\"/>\n</div></div><fieldset><div><i></i><span>Hidden</span></div><legend>Email Lists</legend><div><div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Morning Update\"/>\n<label for=\"choice_2_5_1\">Morning Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Lunch Update\"/>\n<label for=\"choice_2_5_2\">Lunch Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Market Close Update\"/>\n<label for=\"choice_2_5_3\">Market Close Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Weekend Update\"/>\n<label for=\"choice_2_5_4\">Weekend Update</label>\n</div></div></div></fieldset><div><label for=\"input_2_3\"></label><div></div></div></div></div>\n<div> <input type=\"submit\" value=\"Submit\"/> <input type=\"hidden\" value=\"form_id=2&amp;title=&amp;description=&amp;tabindex=0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"2\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"WyJbXSIsImQ5ODZkNzIwYjIxZjU4YzcxYzQzNTI1YjUzYTViYTYxIl0=\"/>\n<input type=\"hidden\" value=\"0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"\"/>\n</div>\n</form>\n</div>\n<p>\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t</p>\n</div>\n</div>\n<div>\n<p>\n\t\t\t\t\t\t\tBy proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.\n\t\t\t\t\t\t</p>\n</div>\n</div>\n</div>\n</div>\n</div><div> <h3>Featured Companies</h3> <ul><li> <span>ASX: PTX</span> <span>Prescient Therapeutics </span> </li></ul></div><div> <div> <h2>You might be interested in</h2> </div> <div><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics.jpg 1200w\" width=\"300\"/> </div> <header> <p>Year in Review</p> <h2>Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke</h2> <p> <span> <time datetime=\"2022-12-01 10:24:20\">December 1, 2022</time> <time datetime=\"2022-12-01 12:47:22\" december=\"\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust.jpg 1200w\" width=\"300\"/> </div> <header> <p>Prepped and Primed</p> <h2>2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner</h2> <p> <span> <time datetime=\"2023-01-23 09:30:23\">January 23, 2023</time> <time datetime=\"2023-01-23 13:46:10\" january=\"\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2023/01/Garden-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2023/01/Garden-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden.jpg 1200w\" width=\"300\"/> </div> <header> <p>Health &amp; Biotech</p> <h2>ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow</h2> <p> <span> <time datetime=\"2023-01-20 14:22:59\">January 20, 2023</time> <time datetime=\"2023-01-20 14:22:59\" january=\"\"> </time></span> |      <span> <span> Nadine McGrath </span> </span> </p> </header></article> </div></div>\n<div></div>\n<div></div>\n<div><h2>Sponsored Articles</h2></div>\n</main>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://stockhead.com.au/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/\">Stockheads</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://stockhead.com.au/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/","article_id":"2305968169","we_media_id":null,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-Prescient-1-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2305968169","pubTimestamp":1674515674,"columns":[],"sourceInfo":{"source_id":"stockheads_stock","name":"Stockheads"},"weMediaInfo":null,"summary":"Link copied to clipboardStockhead’s Prepped and Primed video series is a yearly wrap up address from","collect":0,"end_time":0,"defaultTopTitle":"stockhead.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"2023年准备和启动：先见之明治疗（ASX：PTX）与首席执行官和董事总经理史蒂文Yatomi-Clarke","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTX":1},"content_text":"Link copied to clipboardStockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. \nIn this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.\nPrescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.\nTo hear about the company’s upcoming 2023, click above.\n Explore More   Investor Guide: Health & Biotech FY2023  Read MoreHealthLink copied to clipboard\n\n\n\n\n\n\n\nSUBSCRIBEGet the latest Stockhead news delivered free to your inbox. \n\n\n\n\"*\" indicates required fields\n\nName* Email*\n\nHiddenEmail Lists\n\nMorning Update\n\n\nLunch Update\n\n\nMarket Close Update\n\n\nWeekend Update\n\n  \n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t\n\n\n\n\n\t\t\t\t\t\t\tBy proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.\n\t\t\t\t\t\t\n\n\n\n\n Featured Companies  ASX: PTX Prescient Therapeutics    You might be interested in       Year in Review Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke   December 1, 2022   |        Stockhead TV         Prepped and Primed 2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner   January 23, 2023   |        Stockhead TV         Health & Biotech ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow   January 20, 2023   |        Nadine McGrath     \n\n\nSponsored Articles","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}